AbbVie Debt to Equity Ratio 2010-2023 | ABBV
Current and historical debt to equity ratio values for AbbVie (ABBV) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. AbbVie debt/equity for the three months ending December 31, 2023 was 5.02.
| AbbVie Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2023-12-31 |
$124.31B |
$10.40B |
11.96 |
| 2023-09-30 |
$124.09B |
$12.13B |
10.23 |
| 2023-06-30 |
$122.47B |
$12.90B |
9.50 |
| 2023-03-31 |
$121.24B |
$13.30B |
9.11 |
| 2022-12-31 |
$121.52B |
$17.29B |
7.03 |
| 2022-09-30 |
$125.30B |
$16.03B |
7.82 |
| 2022-06-30 |
$128.50B |
$14.69B |
8.75 |
| 2022-03-31 |
$126.90B |
$16.31B |
7.78 |
| 2021-12-31 |
$131.09B |
$15.44B |
8.49 |
| 2021-09-30 |
$135.28B |
$13.58B |
9.96 |
| 2021-06-30 |
$135.38B |
$12.59B |
10.75 |
| 2021-03-31 |
$136.77B |
$13.73B |
9.96 |
| 2020-12-31 |
$137.47B |
$13.10B |
10.50 |
| 2020-09-30 |
$134.33B |
$15.29B |
8.79 |
| 2020-06-30 |
$134.80B |
$14.73B |
9.15 |
| 2020-03-31 |
$98.61B |
$-7.42B |
-13.30 |
| 2019-12-31 |
$97.29B |
$-8.17B |
-11.91 |
| 2019-09-30 |
$67.67B |
$-8.23B |
-8.23 |
| 2019-06-30 |
$65.71B |
$-8.57B |
-7.67 |
| 2019-03-31 |
$64.60B |
$-7.83B |
-8.25 |
| 2018-12-31 |
$67.80B |
$-8.45B |
-8.03 |
| 2018-09-30 |
$69.09B |
$-2.92B |
-23.65 |
| 2018-06-30 |
$65.02B |
$-3.38B |
-19.26 |
| 2018-03-31 |
$65.79B |
$3.55B |
18.52 |
| 2017-12-31 |
$65.69B |
$5.10B |
12.89 |
| 2017-09-30 |
$62.15B |
$6.69B |
9.30 |
| 2017-06-30 |
$60.99B |
$6.01B |
10.15 |
| 2017-03-31 |
$60.67B |
$5.00B |
12.14 |
| 2016-12-31 |
$61.46B |
$4.64B |
13.26 |
| 2016-09-30 |
$60.16B |
$6.47B |
9.30 |
| 2016-06-30 |
$61.57B |
$5.64B |
10.92 |
| 2016-03-31 |
$49.08B |
$4.64B |
10.57 |
| 2015-12-31 |
$49.11B |
$3.95B |
12.45 |
| 2015-09-30 |
$49.97B |
$4.86B |
10.28 |
| 2015-06-30 |
$48.35B |
$5.50B |
8.79 |
| 2015-03-31 |
$25.32B |
$1.38B |
18.39 |
| 2014-12-31 |
$25.77B |
$1.74B |
14.79 |
| 2014-09-30 |
$23.81B |
$4.65B |
5.13 |
| 2014-06-30 |
$23.83B |
$5.22B |
4.57 |
| 2014-03-31 |
$23.96B |
$4.70B |
5.10 |
| 2013-12-31 |
$24.71B |
$4.49B |
5.50 |
| 2013-09-30 |
$24.68B |
$3.58B |
6.90 |
| 2013-06-30 |
$24.35B |
$3.56B |
6.84 |
| 2013-03-31 |
$24.21B |
$2.96B |
8.19 |
| 2012-12-31 |
$23.65B |
$3.36B |
7.03 |
| 2012-09-30 |
$7.06B |
$15.67B |
0.45 |
| 2012-06-30 |
$6.20B |
$11.51B |
0.54 |
| 2012-03-31 |
$6.91B |
$12.05B |
0.57 |
| 2011-12-31 |
$7.59B |
$11.93B |
0.64 |
| 2011-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2011-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2011-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2010-12-31 |
$5.43B |
$15.70B |
0.35 |
| 2009-12-31 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$300.196B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
